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Steve Pascoloa, Emmanuel Contassota, Malgorzata Bobrowicza,b, Wolfram Hoetzeneckerc and
Emmanuella Guenovaa
aDepartment of Dermatology, University Hospital Zurich University of Zurich, Zurich, Switzerland; bDepartment of Immunology,
Medical University of Warsaw, Warsaw, Poland; cDepartment of Dermatology, University Hospital Linz, Linz, Austria
ABSTRACT
In Sezary syndrome (SS) impaired T-cell function and cytokine profile lead to immune evasion.
Immune checkpoints non-redundantly regulate immune responses and targeting them is prom-
ising. We evaluated the expression of BTLA, CTLA-4, FCRL3, LAG-3, and TIGIT in tumor and non-
tumor SS T-cells.Compared to CD4þ T helper cells from ten healthy individuals, tumor cells of
eight SS patients had a significant upregulation of BTLA (1.5-fold; p< .0001), FRCL3 (2.2-fold;
p< .0028) and TIGIT (2.2-fold; p< .0003) expression. In contrast, we found a reduced expression
of LAG-3þ cells in the blood of tumor patients (0.5-fold; p< .0014). Only weak alternations
between tumor, non-tumor cells, and healthy controls were observed regarding CTLA-4
(0.5-fold; p< .2022). Our results show a diverse expression pattern of immune-regulatory mole-
cules in SS patients. As these molecules are essential in the regulation of T-cell mediated tumor
surveillance and defense, their specific targeting might be of clinical relevance.
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Introduction
Sezary syndrome (SS) is a leukemic variant of primary
cutaneous T-cell lymphoma (CTCL) with poor progno-
sis and duration of treatment response ranging from
7.5 to 22.4 months [1,2]. Since impaired immune
responses and increased susceptibility to infections are
a major mortality cause [3], boosting the immune
response is considered a rational therapeutic strategy.
Immune checkpoint inhibitors, especially those tar-
geting PD-1 (programmed death receptor 1) and its
ligand PD-L1 as well as CTLA-4 (cytotoxic T-cell anti-
gen 4), are effective in the treatment of melanoma,
advanced solid tumors and hematologic malignancies
[4–8]. Since overexpression of PD-1 has been shown in
SS [9] and mycosis fungoides (MF) [10], the clinical
benefit of targeting PD-1 and PD-L1 in CTCL is cur-
rently under investigation. Preliminary data showed
response rates in 38% of CTCL (MF and SS) patients
treated with the PD-1 inhibitor pembrolizumab [11].
However, only 15% of the MF and none of the SS
patients responded to treatment with the PD-1 inhibi-
tor nivolumab [4]. Additionally, in a murine T-cell
lymphoma model, PD-1 suppresses oncogenic T-cell
signaling in pre-malignant T-cells, but suppression or
lack of PD-1 or PD-L1 induces lethal lymphoprolifera-
tion of T-cells with oncogenically fully activated T-cell
receptor (TCR) pathways [12]. Since there are multiple
non-redundant immunosuppressive pathways, novel
checkpoint molecules might be potential targets for
immunotherapy of SS [13].
B and T lymphocyte attenuator (BTLA; CD272) is an
inhibitory receptor, engaged in immune tolerance and
immune suppression and is thus expressed in tumor
and non-tumor T-cells. In tumors, BTLA ligation by her-
pesvirus entry mediator (HVEM) blocks T-cell activa-
tion, proliferation, and cytokine production [14].
Further, BTLA predicts poor prognosis in patients with
diffuse large B cell lymphoma [15]. In inflammatory
diseases, restoration of BTLA immune suppressive
functionality improves multiple sclerosis [16], contact
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hypersensitivity [17], lupus [18] and T cell-tolerance
induction to oral antigens [19]. High BTLA expression
is a hallmark of anergic and dysfunctional T
cells [17,20].
Lymphocyte activation gene-3 (LAG-3; CD223) is a
negative regulatory protein for T cell function,
involved in tissue damage prevention and autoimmun-
ity [21]. Its blockade leads to enhanced proliferation of
CD4þ T cells and an increased production of IL-2, IL-4,
and IFN-c [22]. LAG-3 is frequently co-expressed with
PD-1 on tumor-infiltrating lymphocytes (TILs), thus
contributing to immune exhaustion and tumor promo-
tion [23]. Dual blockade of LAG-3 and PD-1 may act
synergistically to reverse T-cell suppression [11],
restore immunity and improve murine chronic
lymphocytic leukemia [24,25]. Currently, two inhibitory
approaches, a LAG-3-Ig fusion protein (IMP321,
ImmuntepVR ) and monoclonal antibodies (mAbs) tar-
geting LAG-3, are under clinical investigation either as
a monotherapy or in combination with anti-PD-1
mAbs for hematologic neoplasms and solid tumors.
T-cell immunoreceptor with Ig and ITIM domains’
(TIGIT) is a poliovirus receptor (PVR)-like protein con-
taining an immune-receptor tyrosine-based inhibitory
motif (ITIM) and an immunoglobulin tail tyrosine (ITT)-
like motif, which both induce inhibitory signals in
T-cells [26]. Specifically, TIGIT ligation was shown to
impair Th1 activity, to enhance Th2 function and to
stimulate the suppressive function of Tregs [27–30].
Accordingly, TIGIT-deficiency in mice results in hyper-
proliferative T-cell responses, enhanced Th1 activity,
increased susceptibility to autoimmunity and reduced
tumor growth [23,28]. TIGIT overexpression on TILs
correlates with advanced tumor stage in solid tumors
[31,32] and in hematological malignancies [33–35].
Fc receptor-like 3 (FCRL3; CD307c) is a member of
the Fc receptor-like (FCRL) family of classical FcR
homologs. Its expression is found on human B cells, T
memory cells, and NK cells [36,37]. Although its
physiological function is not yet completely eluci-
dated, FCRL3 has been related to the regulation of
immune responses and autoimmune diseases [38].
In CTCL, the role of immunosuppressive pathways
and the expression of checkpoint molecules on tumor
and especially non-tumor T cells is unclear. Preliminary
data suggest enhanced FCRL3, TIGIT, and LAG-3
expression on tumor T-cells [39–42]. BLTA-expression
in T-cells from CTCL patients has not been investi-
gated thus far. Expression of those markers on non-
tumor T-cells from CTCL patients has not
been reported.
Our study aims to characterize the expression of
immune checkpoint inhibitor regulators on tumor-
and non-tumor (TILs) CD4þ T-cells in SS patients.
Materials and methods
Patients
Patients with previously diagnosed eight SS and with
an unequivocally identifiable Vb clonal T-cell popula-
tion were included in the study. Blood samples from
ten healthy individuals served as control. The diagno-
sis of SS was established in all patients according to
the World Health Organization-European Organization
for Research and Treatment of Cancer criteria for SS
[43]. Blood from the patients with SS was obtained
from the University of Z€urich Biobank (EK No. 647).
Blood from healthy individuals was obtained from the
blood bank of the University Hospital Zurich. The
study was conducted in accordance with the princi-
ples of the Declaration of Helsinki and approved by
the Institutional Review Board of the University of
Zurich (KEK-ZH-Nr. 2015-0209).
Flow cytometry
For flow cytometry anti-human monoclonal antibodies
were used as listed: CD3 (clone BW264/56, label
PerCP; Miltenyi Biotec #130-096-910), CD4 (clone VIT4;
label APC-Vio770; Miltenyi Biotec #130-098-153), TIGIT
(clone MBSA43, label APC, eBioscience #17-9500-42),
BTLA (clone MIH26, label APC, BioLegend #344510),
LAG 3 (clone 3DS223H, label FITC, eBioscience #11-
2239-41) and FCRL3 (clone 546828, label APC; R&D
systems #FAB3126A). Vb clonal T-cell populations were
assessed using IOTestVR Beta Mark TCR V beta
Repertoire Kit., (Beckman Coulter, Nyon, Switzerland)
according to the manufacturer’s instructions. Samples
were acquired on Becton Dickinson, Allschwil,
Switzerland FACSCanto instrument. FCS Express 5
Flow Cytometry RUO, Glendale, CA, USA, Origin Pro
9.1G, Northampton, MA, USA and GraphPad Prism 5.0
Software, San Diego, CA, USA were used for
data analysis.
Statistical analysis
Statistical analysis was performed with GraphPad Prism
5.0 Software. For normality testing the Shapiro–Wilk
normality test and the Kolmogorov–Smirnov test were
used. Further analysis included unpaired t-test and the
Mann–Whitney U-test.
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Results
Decreased LAG-3 and increased BTLA, TIGIT, and
FCRL3 expression on total CD4þ blood T-cells
from patients with Sezary syndrome
First, we assessed the fluorescence intensity of BTLA,
CTLA-4, FCRL3, LAG-3, and TIGIT staining on all periph-
eral CD4þ blood T-cells isolated from SS patients.
Peripheral blood T-cells isolated from blood samples
donated by healthy individuals served as a control.
The median fluorescence intensity (MFI) of LAG-3
expression was significantly lower on the cell surface
of CD4þ T-cells from SS patients compared to CD4þ
T-cells isolated from the blood of healthy donors
(p< .0014) (Figure 1(A)). In contrast, the intensity of
expression for BTLA (p< .0001) (Figure 1(B)), FCRL 3
(p< .0028) (Figure 1(C)) and TIGIT (p< .0003) (Figure
1(D)) was significantly higher on the cell surface of
CD4þ T-cells from SS patients as compared to controls
(Figure 1(A)). Although we observed a tendency for
decreased intensity of CTLA-4 expression on CD4þ T-
cells from SS patients, the differences were not statis-
tically significant (p¼ .2022) (Figure 1(E)).
Expression of immune checkpoint molecules on
clonal (tumor) vs. non-clonal (non-tumor) CD4þ
cells in Sezary syndrome
In SS patients, the peripheral CD4þ T-cell compartment
contains the clonally expanded tumor T-cells as well as
the non-clonal bystander CD4þ T-cells. To analyze the
pattern and fluorescence intensity of immune check-
point molecules’ expression on tumor and bystander
T-cells, we identified patients with a conclusively identi-
fiable malignant T-cell clone with commercially avail-
able TCR Vb antibodies for flow cytometry. Table 1
summarizes the patients’ clinical characteristics.
LAG-3 was downregulated on both clonal and non-
clonal CD4þ T-cells from SS patients as compared to
CD4þ T-cells from healthy controls. The mean MFI for
LAG-3 was 294.8 ± 143.4 (153.2–516.1) in clonal,
292.8 ± 209.8 (170.8–766) in non-clonal and
652.7 ± 234.5 (409.4–1225) in healthy controls (Figure
2(A)). In addition, the percentage of LAG-3þ cells was
lower for both clonal and non-clonal CD4þ T-cells
from SS patients, respectively 5.496%±6.6 (1.22–20.02)
and 3.92%±7.4 (0.04–20.52) LAG-3þ cells (Figure 2(B)).
In contrast, in healthy controls, 25.6%±10.68
(11.99–45.94) of all CD4þ T-cells expressed LAG-3
(Figure 2(B)). Taken together, LAG-3 was statistically
significantly downregulated on both clonal and non-
clonal CD4þ T-cells from SS patients (p< .0007).
However, the interindividual differences of LAG-3
expression between clonal and non-clonal were not
statistically significant.
In contrast to the global downregulation of LAG-3,
all other studied immune checkpoint molecules - BTLA,
Figure 1. Divergent level of LAG-3 versus BTLA, TIGIT, and
FCRL3 expression on total CD4þ blood T-cells from patients
with Sezary syndrome. LAG-3, BTLA, FCRL3, TIGIT, and CTLA-4
expression in blood CD4þ T-cells from patients with Sezary
syndrome (SS) and healthy individuals (nml) was analyzed by
flow cytometry. Left panels show significantly decreased mean
fluorescence intensity (MFI) of LAG-3 (A) and increased MFI of
BTLA (B), FCLR3(C) and TIGIT (D) on CD4þ T-cells from SS
patients (in red) compared to CD4þ T-cells from healthy
donors (in black). Each dot represents data obtained from one
individual. Right panels show representative histograms of
mean fluorescent intensities of LAG-3 (A), BTLA (B), FCLR3(C),
TIGIT (D) and CTLA-4 (E) in CD4þ blood T-cells from SS
patients (in red) and healthy individuals (in black).
BTLA, TIGIT, FCRL3 AND LAG-3, EXPRESSION IN SS 1901
FCRL3, and TIGIT were upregulated on both clonal and
non-clonal CD4þ T-cells from SS patients.
With regard to BTLA, there was a significantly
increased staining intensity in clonal and non-clonal
cells (4949 ± 825.4 (3459–6137); 5478 ± 1086
(3432–6344)) compared to healthy controls
(3245 ± 437.9; 2489–3876) (p< .0001) (Figure 2(C)). In
line with this, the percentage of BTLA expressing cells
from SS patients was significantly higher in clonal cells
with 52.65%±13.91 (26.63–72.77), as well as in non-clo-
nal cells with 59.61%±15.30 (29.76–70.89) than the
percentage of BTLA expressing CD4þ T-cells from
healthy individuals (p¼ .0005) (Figure 2(D)).
TIGIT and FCRL3 upregulation on both clonal and
non-clonal SS CD4þ T-cells synchronous to BTLA upre-
gulation. Intensity of FCRL 3 expression was high in
non-clonal cells (2112 ± 735.1; 807.1–2978) and clonal
CD4þ SS T-cells (1949± 1140; 436.5–3956) compared
with T-cells from healthy individuals (892 ± 285.2;
460–1310) (Figure 2(E)). In addition, the percentage of
FCRL3 expressing cells was higher in both clonal
(12.47%±15.18 (0.71–41.73)) and non-clonal
(10.29%±7.32 (2.28–21.14)) CD4þ SS T-cells than in
healthy individuals (12.68%±12.34 (1.93–36.09)) (Figure
2(F)). Both clonal and non-clonal CD4þ T-cells isolated
from SS patients stained more intensively for TIGIT
than CD4þ T-cells isolated from healthy donors
(2014 ± 604; 1099–3028; p< .0001) (p< .0006) (Figure
2(G)). Although there was a tendency for more intense
TIGIT expression on clonal tumor cells compared to
non-clonal bystander cells, the intra-individual differ-
ence in the intensity of TIGIT expression (MFI)
between clonal (4583 ± 1833; 3166–8362) and non-clo-
nal T-cells (3419± 1384; 2290–6380) was not signifi-
cant in this patients’ cohort (p< .0973) (Figure 2(G)).
Also, the percentage of TIGIT expressing CD4þ T-cells
was significantly higher in total CD4þ T-cells from SS
patients (47.45%±16.66 (25.84–78.26)) compared to
healthy controls (26.49%±9.892 (14.19–39.80))
(p¼ .0043; data not shown). There was a distinct trend
of higher TIGIT expression in clonal T-cells
(53.61%±19.02 (32.94–85.04)) as compared to non-clo-
nal T-cells (36.14%±20.09 (17.56–77.27)), but the differ-
ences were not statistically significant in this patients’
cohort (Figure 2(H)).
There was no statistically significant difference in
either intensity of CTLA-4 expression or percentage
cells expressing CTLA-4 on clonal versus non-clonal T-
cells form SS patients (data not shown).
Intraindividual comparison of immune checkpoint
molecule expression on clonal (tumor) vs. non-
clonal (non-tumor) CD4þ cells in Sezary syndrome
Variability and difficulty in collecting large numbers of
human samples in a rare disease setting, such as SS,
renders comparisons on an interindividual level chal-
lenging. For an intraindividual comparison, we ana-
lyzed the differences in the level of expression of LAG-
3, BTLA, TIGIT, and FCRL3 on malignant, clonal T-cells
and bystander, non-clonal T-cells in the blood of each
individual patient with SS. Detailed pair-wise compari-
son showed slightly decreased expression of LAG-3 in
43% of all patients (Figure 3(A)). Expression of BTLA,
FCRL3, and TIGIT was upregulated on the tumor T-cells
in 29% (Figure 3(B)), 43% (Figure 3(C)) and 86%
(Figure 3(D)) of the patients.
Discussion
SS is a malignancy of mainly CD4þ T-cells and CD4þ
T cells play an essential role in promoting effector
immune responses. In solid tumors, CD4þ Th1 cells
Table 1. Patients’ characteristics.
Pat.
No.
TCR
clone
Clonal
cells [%]
Age at diagnose
[years]/sex
CD4/CD8
ratio
CD4þ
CD7- [%]
Total
lymphocyte
count Treatment
Survival after
diagnosis
[years]
1 Vb22 50.18 61/M 1.5 1 1.224 Extracorporeal photopheresis
(ECP), Interferone alpha-2,
Interferone gamma-1b,
Bexarotene, Alitretinoin
3
2 Vb8 33.77 61/M 23.7 82 1806 MTX, PUVA, ECP, IFN, D, B 5
3 Vb1 94.98 68/F 2.4 15 3579 ECP, Interferone alpha-2 4.5
4 Vb20 37.26 63/M 0.7 11 1116 ECP, systemic steroids 1
5 Vb13.2 70 56/M 46.9 91 18776 ECP, Interferone alpha-2 4.5
6 Vb2 60 71/M 1.5 1 1344 ECP, Interferone alpha-2,
Interferone gamma-1b,
Alitretinoin, systemic steroids
4.5
7 Vb14 91.5 65/F 10 1 3905 ECP, systemic steroids, MTX,
Interferone alpha-2
4.5
8 Vb1 73 78/F 9.8 18 1286 ECP, Bexarotene 10.5
TCR: T-cell receptor; IFN: interferon; ECP: extracorporeal photochemotherapy; MTX: methotrexate; PUVA: psoralenþUVA treatment.
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drive tumor senescence [44]. In SS, malignant CD4þ
cells lose their ability to acquire a Th1 phenotype,
may acquire features of Tregs and IL-17 production
[45], they secrete Th2 cytokines and enforce immune
suppression and a global Th2 bias in non-tumor T-cells
[46,47]. Continuous antigen presentation by immature
dendritic cells may lead to T-cell exhaustion in CTCL
[47], followed by silencing of T-cells mediated immune
responses, decreased cytokine secretion of TNF-a, IL-2,
and IFN-c by memory T-cells and subsequent uncon-
trolled progression of infections, inflammatory, and
tumor processes [48–50]. Exhaustion may also result in
an inefficacy of CAR T cells or other novel treatment
modality [51].
In acute myeloid leukemia, T cell exhaustion of
bystander CD8þ lymphocytes has been discussed [52].
In SS patients, CD8þ cells down-regulate activation
markers CD127/IL-7R and CD26 and remained unre-
sponsive to IL-7 stimulation. This has been attributed
to their chronic activation due to the massive prolifer-
ation of malignant CD4þ T cells [53].
T-cell exhaustion can be temporary and effective T-
cell responses can be restored by a pharmacologic
inhibition of the inhibitory receptors: CTLA-4, PD-1,
TIGIT, LAG-3, BTLA, TIM3, and PD-1H [50].
We investigated the expression of the checkpoint
molecules BTLA, CTLA-4, FCRL3, LAG-3, and TIGIT on
blood T helper subsets from SS patients. We observed
a previously non reported and significant increases in
the expression of BTLA on both tumor and non-tumor
T-cells from SS patients. In parallel, we further found
increased FCRL3 and TIGIT expression in SS tumor
cells. These results are in line with the work of
Jariwala et al. documenting the high expression of
FRCL3 and TIGIT on CD4þ SS cells [40]. Also, Wysocka
et al. reported FCRL3 expression in patients with high
tumor burden [41]. In these studies, TIGIT and/or
FCRL3 expression showed a correlation with an
increase in single TCRVbþCD4þ cells or loss of CD26
expression [40]. However, in our patients’ cohort, both
TIGIT and FCRL3 were found to be similarly upregu-
lated on both tumor and bystander CD4þ T-cells, des-
pite a distinct trend for the higher expression of BTLA
and TIGIT in clonal cells. On the one hand, this lack of
significance may be attributed to the small number of
patients included in the study. On the other hand, the
fact that non-clonal CD4þ cells also overexpress nega-
tive checkpoint regulators suggests that bystander
CD4þ cells also have an immunosuppressive pheno-
type, which could contribute to the ineffective
immune response observed in SS patients.
In line with this, an elegant study by Querfeld et al.
assessing the expression profile of immune check-
points in CTCL skin samples suggested that the
exhaustion phenotype is a common characteristic of
both helper and cytotoxic CTCL skin cells [10]. In that
study, gene expression profiling demonstrated upre-
gulation of several immune checkpoints (PD-1, PD-L1,
Figure 2. Expression of immune checkpoint molecules on clo-
nal (tumor) vs. non-clonal (non-tumor) CD4þ cells in Sezary
syndrome. CD4þ T-cells were isolated either from healthy
donors (blue dots) or from SS patients. In blood samples from
SS patients, CD4þ TCRVbþ clonal tumor (red dots) and CD4þ
TCRVb- non-tumor (black dots) T lymphocytes were identified
by TCR Vb specific antibodies for flow cytometry. (A)
Evaluation of the differences in the mean fluorescence inten-
sity (MFI) for each marker of interest between healthy, clonal,
and non-clonal T-cells. (B) Assessment of the differences in the
percentage of positive for each marker of interest cells in the
above defined T-cell populations.
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TIM2, CTLA-4, LAG-3) and IL-10 in advanced CTCL [10].
Additionally, in flow cytometry, there were increased
percentages of CD4þ PD-1, CTLA-4, and LAG-3
expressing cells and more CTLA-4 and LAG-3 express-
ing CD8þ cells as compared to healthy controls [10].
Interestingly, CTCL skin also contained more T-cells
expressing the inducible T-cell costimulator (ICOS), a
marker of T-cell activation [10]. Altogether, this inform-
ative analysis postulates that in CTCL skin, exhaustion
of activated T-cells being a hallmark of both skin
Figure 3. Intraindividual comparison of immune checkpoint molecules’ expression on clonal (tumor) vs. non-clonal (non-tumor)
CD4þ cells in Sezary syndrome. (A) Pair-wise analysis of medium fluorescence intensity (MFI) in non-clonal and clonal CD4þ
T-cells. Each color-indexed pair represents a data set from an individual patient with SS. (B) Representative example of flow cyto-
metric identification of the malignant T-cell clone (red) and non-clonal T-cells (black) by staining with T-cell receptor Vb antibodies
specific for each patient’s malignant clone and evaluation of the differences in percentages of positive cells for each marker of
interest between clonal and non-clonal T-cells.
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CD4þ and CD8þ T-cells, the expression of checkpoint
inhibitors increasing during the course of the disease
progression. While Querfeld et al. observed increased
LAG-3 expression in lesional MF skin samples, in our
study, SS cells showed a decreased intensity of LAG-3
staining and a decrease in the percentage of LAG-3
expressing CD4þ blood T-cells. This may be explained
by the fact that MF and SS arise from distinct T-cell
subsets [54] but nevertheless should be further investi-
gated in larger comparative cohorts.
By now, several advanced clinical studies address
TIGIT as a target molecule. In our view, this concomi-
tant targeting of malignant clonal and bystander
CD4þ cells along with unblocking the response of
CD8þ cells and boosting NK cell activity holds remark-
able potential in CTCL as well.
The hitherto non-reported overexpression of BTLA
in SS is of interest, as BTLA-blockade would arrest T-
cell proliferation and hypothetically, in the case of SS
patients, malignant T-cells would be specifically tar-
geted. Recently, a specific fragment (HVEM 26–28),
which is involved in the binding of the BTLA/HVEM
complex has been designed to block the interaction
of BTLA and HVEM in vitro [55]. However, to our
knowledge no in vivo studies have been conducted
so far.
Altogether, we identify BTLA and confirms LAG-3
and TIGIT as potential immune modulatory targets for
therapy of CTCL and specifically of SS. As immune
checkpoints have non-redundant roles in cancer pro-
gression, other emerging regulatory molecules (TIM-3,
CD96 (TACTILE), PD-1H (VISTA)) may be of interest in
CTCL too.
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